Predictive Oncology

Predictive Oncology is a science-driven company operating in the field of oncology drug discovery. Its offerings encompass an extensive suite of solutions tailored for the biopharmaceutical industry. At the core of Predictive Oncology's approach lies the integration of rigorous scientific methods and machine learning, facilitated by the world's largest privately-owned biobank consisting of over 150,000 tumor samples. This unique combination enables the company to advance molecules into medicine more reliably by introducing human diversity earlier in the discovery process.

Predictive Oncology's capabilities span various domains, including tumor models, biologics development, formulation design, a GMP facility, and a CLIA-certified laboratory. Additionally, the company leverages artificial intelligence (AI) and machine learning techniques through its PEDAL platform. This proprietary technology enables drug discovery, contributing to Predictive Oncology's comprehensive suite of solutions.

In February 2023, Predictive Oncology formed a strategic partnership with CvergenX, aiming to revolutionize the field of radiation oncology. By combining their respective expertise in AI, machine learning, and precision genomics, the companies seek to develop the first-ever genomics-based approach to personalized radiotherapy and drug discovery. This collaboration has the potential to optimize radiotherapy prescription doses, identify radiosensitizers, and uncover radioprotectors, ultimately improving patient outcomes.